213819-48-8
213819-48-8 結(jié)構(gòu)式
基本信息
鹽酸貝路替康
貝洛替康鹽酸鹽
CKD-602 鹽酸鹽
TOPOISOMERASE I抑制劑(BELOTECAN HYDROCHLORIDE)
(S)-4-乙基-4-羥基-11-(2-(異丙氨基)乙基)-1H-吡喃并[3',4'：6,7]吲哚并[1-2,b]喹啉-3,14(4H,12H)-二酮鹽酸鹽
(S)-4-乙基-4-羥基-11-[2-(異丙基氨基)乙基]-3,4,12,14-四氫-1H-吡喃并[3',4':6,7]氮茚并[1,2-B]喹啉-3,14-二酮鹽酸鹽
(S)-4-乙基-4-羥基-11-[2-(異丙基氨基)乙基]-3,4,12,14-四氫-1H-吡喃并[3',4':6,7]中氮茚并[1,2-B]喹啉-3,14-二酮鹽酸鹽
CKD-602
CKD 602
CKD602
Belotecan Hydrochlorid
Camtobell hydrochloride
BELOTECAN HYDROCHLORIDE
(S)-7-methylcamptothecin
CKD-602: BELOTECAN HYDROCHLORIDE
Belotecan hydrochloride(CKD-602)
(S)-4-Ethyl-4-hydroxy-11-(2-(isopropylamino)ethyl)-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol
(S)-4-Ethyl-4-hydroxy-11-[2-(isopropylamino)ethyl]-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-dione hydrochloride
物理化學(xué)性質(zhì)
常見問題列表
CKD-602 鹽酸鹽是一種新型喜樹堿衍生物抗腫瘤藥物。盡管ckd -602在臨床中應(yīng)用更廣泛，但靜脈輸注引起的ckd -602相關(guān)毒性尚未得到評(píng)估。
| Target | Value |
|
DNA topoisomerase I
() |
Belotecan exerts a significant cytotoxic effect on YD-8, YD-9 and YD-38 cells in a time- and dose-dependent manner with IC 50 values of 2.4, 0.18 and 0.05 μg/mL at 72 h following treatment. Belotecan induces apoptosis in these cell lines. Belotecan induces G2/M phase arrest in oral squamous cell cancer cells. Belotecan shows a significant anticancer effect on glioma cells, with IC 50 values of 9.07 nM for LN229, 14.57 nM for U251 MG, 29.13 nM for U343 MG, and 84.66 nM for U87 MG.
Belotecan has a significant effect on intracerebral glioma growth, with animals having significantly smaller tumors than those in the control group.
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2026/07/06 | S6631 | CKD-602 鹽酸鹽 Belotecan (CKD-602) hydrochloride | 213819-48-8 | 5mg | 1204.53元 |
| 2026/07/06 | S6631 | CKD-602 鹽酸鹽 Belotecan (CKD-602) hydrochloride | 213819-48-8 | 25mg | 3743.68元 |
| 2026/06/05 | HY-13566A | CKD-602 鹽酸鹽 Belotecan hydrochloride | 213819-48-8 | 1 mg | 548元 |